Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial

Type 1 diabetes is a common autoimmune disease due to destruction of pancreatic β cells, resulting in lifelong need for insulin. Evidence suggest that maintaining residual β-cell function can improve glucose control and reduce risk of hypoglycaemia and vascular complications. Non-clinical, preclinic...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Wellcome Open Res
Main Authors: Marcovecchio, M. Loredana, Wicker, Linda S., Dunger, David B., Dutton, Susan J., Kopijasz, Sylwia, Scudder, Claire, Todd, John A., Johnson, Paul R. V.
Format: Artigo
Jezik:Inglês
Izdano: F1000 Research Limited 2020
Teme:
Study Protocol
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7194454/
https://ncbi.nlm.nih.gov/pubmed/32399500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12688/wellcomeopenres.15697.1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki